# Postprandial Hypotension is Attenuated with Acarbose Treatment in Older Adults with Diabetes Mellitus type 2: a Randomized Controlled Crossover Cohort Study **Research Institute**

### Abstract

Vancouver

CoastalHealth

Healthier lives through discovery

Postprandial hypotension (PPH) is common in older adults and those with autonomic dysfunction, commonly with Diabetes Mellitus (DM). This study proposed to demonstrate that Acarbose, an  $\alpha$ -glucosidase inhibitor, decreases the degree of PPH in an elderly DM cohort. 15 adults (9 women, 6 men) with average age of 76.06 years (range: 67-85.2) with DM type 2 (Duration: 8.7 years ±7.4 ; Hemoglobin A<sub>1</sub>C 6.9%±0.8) attended a treatment and placebo session (separate days at least two weeks apart) in random double-blinded order. Subjects were fed a standardized meal (4°C) and then continuously monitored over 90 minutes for blood pressure by Finometry, heart rate by Electrocardiogram, and middle cerebral artery blood flow velocity by transcranial Doppler Sonogram (20-minute baseline recorded for all measurements), blood glucose and catecholamine measurements. The frequency of PPH occurring per study was 0.8 (range: 1-3) for Acarbose and 1.46 (range: 0-3) for placebo (p=0.0359). The hemodynamic response of systolic blood pressure (SBP) and mean arterial pressure (MAP) (baseline as covariante) was significantly different by mixed-model repeated measures two-factor (time and treatment) analysis of variance (SBP: *p*=0.0295; MAP: *p*=0.0354). This is the first study to demonstrate Acarbose attenuates PPH in adults with DM. Our results suggest that acarbose is a potential therapy for PPH in older adults with DM type 2. The reported higher prevalence of PPH in our study warrants further investigation.

## Background

Postprandial hypotension (decreased systolic blood pressure ≥20 mmHg or in systolic blood pressure <90 mmHg when previously  $\geq$ 100 mmHg within 2 hours after meal) is common in institutionalized older adults (>75 years old)<sup>1,4</sup> contributing to syncope, falls, cardiac events/ stroke, and increased mortality<sup>2-8</sup>. Proposed mechanisms include blunted gastrovascular sympathetic reflex post-meal<sup>9,10</sup> or decreased Incretin/gut vasoactive hormone<sup>11</sup>.

## Hypothesis

Acarbose, an  $\alpha$ -Glucosidase inhibitor attenuates PPH in older adult patients with Diabetes Mellitus type 2.

## Subjects

**Subjects:** 15 older adults (9 women, 6 men). **Inclusion:** Age  $\geq$  65 years; Diabetes Mellitus type 2 **Exclusion:** Parkinson's disease; End-stage renal disease ± intermittent hemodialysis; Fragile-X mutation Subjects provided written and informed consent and protocol was approved by the Vancouver Coastal Health clinical research ethics board

# Harris DE<sup>1</sup>, Lockhart C<sup>2</sup>, Meneilly GS<sup>2</sup>, Madden KM<sup>2</sup> <sup>1</sup>Division of Endocrinology, <sup>2</sup>Division of Geriatric Medicine, University of British Columbia, Vancouver, British Columbia, Canada







#### Discussion

- The prevalence of PPH in our study was high as 14 subjects (93.3%) experienced at least one episode of PPH during the Acarbose (10/15) or Placebo (11/15) sessions.
- This higher prevalence may be explained by the use of continuous Finometry to detect PPH as opposed to intermittent brachial sphygmomanometry<sup>11</sup>.
- Acarbose therapy attenuated the mean total frequency of PPH events (0.8 events/subject) as compared to placebo (1.5 events/ subject).
- Acarbose therapy significantly increased systolic and mean arterial blood pressure by 15mmHg and 10.3mmHg, respectively as compared to placebo.
- Systolic, diastolic, and mean arterial middle cerebral artery velocities unexpectedly and significantly decreased with Acarbose therapy as compared to placebo; however, only 8 subjects completed transcranial sonographic analysis as 7 subjects had poor sonographic right temporal bone "windows".
- Administration of Acarbose as a single dose had no significant effect on post-prandial rise in plasma glucose and norepinephrine.
- Future considerations: Acarbose administration >2 weeks prior to conducting our protocol; Mesenteric artery sonographic blood velocity monitoring; inclusion of incretin analysis.

## Conclusion

Acarbose attenuates postprandial hypotension in older adults with

## References

- 1. Lipsitz, LA et al. Postprandial reduction in blood pressure in the elderly. NEJM. 1983;309(2):81-83
- 2. Puisieux F et al. Ambulatory blood pressure monitoring and postprandial hypotension in elderly persons with falls or syncope. J Gerontol A Biol Sci Med Sci. 2000;55:M535-M540.
- 3. Le Couteur DG et al. Postprandial systolic blood pressure responses of older people in residential care: association with risk of falling. Gerontology. 2003;49:260-264.
- 4. Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med. 1995;122:286-295.
- 5. Lipsitz LA et al. Cardiovascular and norepinephrine responses after meal consumption in elderly (older than 75 years) persons with postprandial hypotension and syncope. Am J Cardiol. 1986;58:810-815.
- 6. Aronow WS, Ahn C. Association of postprandial hypotension with incidence of falls, syncope, coronary events, stroke, and total mortality at 29-month follow-up in 499 older nursing home residents. J Am Geriatr Soc. 1997;45:1051-1053.
- 7. Kohara K et al. Postprandial hypotension is associated with asymptomatic cerebrovascular damage in essential hypertensive patients. Hypertension. 1999;33:565-568.
- 8. Fisher AA et al. Postprandial hypotension predicts all-cause mortality in older, low-level care residents. J Am Geriatr Soc. 2005;53:1313-1320.
- 9. Luciano, G et al. Postprandial Hypotension. Am J Med. 2010;123(3):281e1-e6
- 10. Fagius J et al. Increase in muscle nerve sympathetic activity after glucose intake is blunted in the elderly. Clin Auton Res. 1996;6:195-203.
- 11. Gentilcore D et al. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med. 2005;118:1289e5-e11.